Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
Illustrative photo Boehringer Ingelheim Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast ...
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Boehringer Ingelheim today revealed that the FIBRONEER-ILD trial of nerandomilast met its primary endpoint, which was the ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...
Findings showed treatment with nerandomilast led to a significant improvement in lung function compared with placebo. Topline data were announced from a phase 3 trial evaluating nerandomilast ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback